2型糖尿病并慢性心功能不全患者应用曲美他嗪治疗疗效及对BNP、FBG、HbA_(1c)指标水平的影响分析

Effect of Trimetazidine on BNP, FBG and Hba1c in Patients with Type 2 Diabetes Mellitus and Chronic Heart Failure

目的研究分析应用曲美他嗪在治疗2型糖尿病并慢性心功能不全患者中的疗效,并对患者指标中血浆脑钠肽(BNP)、空腹血糖(FBG)以及糖化血红蛋白(HbA1c)的情况进行分析。方法选取68例东部战区总医院于2017年1月—2019年12月收治的2型糖尿病并慢性心功能不全的患者,将患者一般资料上传至计算机后应用计算机随机选择的方式将其分为常规组(34例,给予患者常规治疗)与研究组(34例,在常规治疗基础上加用曲美他嗪),比较两组患者治疗前后BNP、FBG、HbA1c水平、治疗效果以及治疗后不良事件发生率。结果经治疗后可知,两组患者治疗前BNP、FBG、HbA1c水平比较差异无统计学意义(P>0.05);在完成治疗后两组以上指标水平均得到有效改善,同时比较两组情况,研究组患者各指标均低于常规组;同时研究组患者经治疗后的总有效率以及不良事件发生率(97.06%、5.88%)均优于对照组(79.41%、23.53%),差异有统计学意义(P<0.05)。结论通过在对2型糖尿病并慢性心功能不全的患者的常规治疗方案基础上应用曲美他嗪,能够更加有效地改善患者指标中BNP、FBG、HbA1c的水平,不仅能够提高治疗效率,还能避免治疗后不良事件的发生。

Objective To study and analyze the therapeutic effect of trimetazidine in the treatment of patients with type 2 diabetes mellitus and chronic heart failure,and to analyze the plasma BNP,FBG and HbA1c in patients.Methods 68 patients with type 2 diabetes mellitus and chronic cardiac insufficiency admitted to the hospital from January 2017 to December 2019 were randomly divided into two groups:the conventional group(34 patients,who were given routine treatment)and the research group(34 patients,who were given trimetazidine on the basis of routine treatment).BNP,FBG,HbA1c,therapeutic effect and incidence of adverse events before and after treatment of the two groups were compared.Results After treatment,there was no significant difference in BNP,FBG and HbA1c levels between the two groups before treatment(P>0.05).After treatment,the above indicators in the two groups were effectively improved.At the same time,compared with the situation in the two groups,the indicators in the study group were lower than those in the conventional group;at the same time,the total effective rate and the incidence of adverse events in the study group(97.06%,5.88%)were all lower,which was better than(79.41%,23.53%)in the control group,the difference of the above data was significant(P<0.05).Conclusion Trimetazidine can effectively improve the BNP,FBG,HbA1c levels in patients with type 2 diabetes mellitus and chronic cardiac insufficiency based on the conventional treatment plan,which can not only improve the treatment efficiency,but also avoid the occurrence of adverse events after treatment.